You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site.

Continue

Go back

Shingrix Logo

Product menu

woman jogging

Age-related decline in immunity puts patients 50 years of age and older at an increased risk of developing shingles.1,2

There is a 1 in 3 lifetime risk of the dormant varicella-zoster virus reactivating and causing shingles.3,4

As age increases, varicella-zoster virus-specific cellular immunity declines, leading to an increased risk of developing shingles.1

age related decline in immunity graph age related decline in immunity graph

Do you know the impact shingles could have on your patients 50 years of age and older?

90% of adults in Ireland are infected with the virus that causes shingles.4

There is a 1 in 3 lifetime risk of the dormant varicella-zoster virus reactivating and causing shingles.3

shingles complications on skin
shingles complications on skin

Images above show patient examples of shingles induced unilateral vesicular (fluid filled blisters) rash.

Post-herpetic neuralgia (PHN)

Following the rash, persistent pain at the site, known as PHN, can develop and is seen more frequently in older people. PHN is described as pain that persists for more than 30 days after the acute infection.13

Affects about 20% of patients with shingles and is the most common complication of shingles.2

PHN can last for months, but can persist for longer.13

Other complications may also occur.

Ocular: Herpes zoster ophthalmicus affects approximately 10-20% of patients with shingles.5

Cutaneous: e.g. bacterial superinfection, scarring.6

Neurological: e.g. hearing/sensory loss, transverse myelitis, cranial/peripheral nerve palsies.6

Visceral: e.g. bronchitis, peritonitis.6

SHINGRIX is the first and only non-live shingles vaccine to combine a recombinant antigen with an adjuvant system generating a strong and sustained immune response in adults 50 years of age and older.7-10

vaccine component details vaccine component details

Learn more about SHINGRIX

90% efficacy visualisation

How efficacious is SHINGRIX?

SHINGRIX demonstrated >90% efficacy against shingles in adults 50 years of age and older based on pooled data from two large, phase 3 randomised controlled trials.7,9,10

review efficacy data

patient profiles icon

Who can benefit from SHINGRIX?

There is a 1 in 3 lifetime risk of developing shingles.3,4 Age-related decline in immunity puts patients 50 years of age and older at an increased risk of developing shingles.1,2

View Patient Profiles

red cross icon for safety

Learn more about the safety profile of SHINGRIX

The majority of local and systemic adverse reactions were mild to moderate and transient, based on two large, phase 3 randomised controlled trials. Reactions reported as severe lasted 1 to 2 days.7,9,10

Explore safety data

References

  1. Kimberlin DW, Whitley RJ. Varicella-zoster vaccine for the prevention of herpes zoster. N Engl J Med. 2007 Mar;356 (13): 1338-43.
  2. Gauthier et al. Epidemiology and costs of herpes zoster and postherpetic neuralgia in the United Kingdom . Epidemiol infecti. 2009; 137: 38-472.
  3. Harpaz R, et al. MMWR Recomm Rep. 2008 June;57(RR-5):1-30. 2. Zerboni L, et al. Nat Rev Microbiol. 2014 Mar;12 (3):197-210.
  4. Bollaerts K et al. A systematic review of varicella seroprevaience in European countries before universal childhood immunization: deriving incidence from seroprevaience data. Epidemiol. Infect. (2017), 145, 2666-2677.
  5. Johnson et al. 2015. Herpes zoster epidemiology, management, and disease and economic burden in Europe: a multidisciplinary perspective. Vol. 3 (4): 109–120.
  6. Volpi A. Severe complications of herpes zoster. Herpes. 2007 Sep;14 Suppl 2: 35-9.
  7. Shingrix, Summary of Product Characteristics (SPC), available on https://www.medicines.ie/medicines/shingrix-powder-and-suspension-for-suspension-for-injection-herpes-zoster-vaccine-recombinant-adjuvanted--35192/spc. Last Accessed: May 2022.
  8. Chlibek R, Smetana J, Pauksens K, Rombo L, Van den Hoek JA, Richardus JH, et al. Safety and immunogenicity of three different formulations of an adjuvanted varicella-zoster virus subunit candidate vaccine in older adults: a phase II, randomized, controlled study. Vaccine. 2014 Mar; 32 (15): 1745-53.
  9. Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang S-J, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015 May;372 (22): 2087-96.
  10. Cunningham AL, Lal H, Kovac M, Chlibek R, Hwang S-J, Diez-Domingo J, et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med. 2016 Sep;375 (11): 1019-32.
  11. Dendouga N, Fochesato M, Lockman L, Mossman S, Giannini SL. Cell-mediated immune responses to a varicella-zoster virus glycoprotein E vaccine using both a TLR agonist and QS21 in mice. Vaccine. 2012 Apr;30 (20): 3126-35.
  12. Leroux-Roels I, Leroux-Roels G, Clement F, Vandepapelière P, Vassilev V, Ledent E, Heineman TC. A phase 1 /2 clinical trial evaluating safety and immunogenicity of a varicella zoster glycoprotein e subunit vaccine candidate in young and older adults. J Infect Dis. 2012 Oct;206 (8): 1280-90.
  13. DH Green Book ch 28a - Shingles. February 2016. Accessed February 2023

Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie . Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

SHINGRIX is owned by or licensed to the GSK group of companies.
© 2022 GSK group of companies or its licensor.
Trade marks are owned by or licensed to the GSK group of companies.

PM-IE-SGX-WCNT-210002 | Date of Preparation: January 2023